Published in J Biol Chem on September 07, 2003
Identification of cells initiating human melanomas. Nature (2008) 8.28
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. Br J Dermatol (2012) 2.31
ABCB5 is a limbal stem cell gene required for corneal development and repair. Nature (2014) 1.65
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Clonogenic cell subpopulations maintain congenital melanocytic nevi. J Invest Dermatol (2014) 1.42
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res (2011) 1.23
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One (2012) 1.21
Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun (2010) 1.13
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res (2005) 1.12
Cellular and extracellular programming of cell fate through engineered intracrine-, paracrine-, and endocrine-like mechanisms. Biomaterials (2011) 1.08
New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. Mol Cancer (2010) 1.01
Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. Cell Death Dis (2013) 1.00
p-Glycoprotein ABCB5 and YB-1 expression plays a role in increased heterogeneity of breast cancer cells: correlations with cell fusion and doxorubicin resistance. BMC Cancer (2010) 0.99
Lost in migration. Nat Biotechnol (2010) 0.97
ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res (2014) 0.94
Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms. PLoS One (2011) 0.91
Stem cells and targeted approaches to melanoma cure. Mol Aspects Med (2013) 0.90
The type 1 diabetes - HLA susceptibility interactome--identification of HLA genotype-specific disease genes for type 1 diabetes. PLoS One (2010) 0.89
Tumor initiation in human malignant melanoma and potential cancer therapies. Anticancer Agents Med Chem (2010) 0.88
Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos. BMC Biol (2013) 0.88
Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol (2013) 0.87
Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst (2009) 0.86
Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk. Biochem Biophys Res Commun (2013) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun (2010) 0.86
Skin rejuvenation with non-invasive pulsed electric fields. Sci Rep (2015) 0.85
ABCB5 gene amplification in human leukemia cells. Leuk Res (2009) 0.84
Mitochondria as therapeutic targets for cancer stem cells. World J Stem Cells (2015) 0.82
ABCB5 Identifies Immunoregulatory Dermal Cells. Cell Rep (2015) 0.82
Restoring the cornea from limbal stem cells. Regen Med (2015) 0.81
Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5. Mol Pharm (2014) 0.81
Salmonella VNP20009-mediated RNA interference of ABCB5 moderated chemoresistance of melanoma stem cell and suppressed tumor growth more potently. Oncotarget (2016) 0.81
Cancer stem cell metabolism: a potential target for cancer therapy. Mol Cancer (2016) 0.80
The role of Abcb5 alleles in susceptibility to haloperidol-induced toxicity in mice and humans. PLoS Med (2015) 0.79
The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharm Sin B (2014) 0.79
Stem cells in melanoma development. Cancer Lett (2008) 0.78
The multidrug-resistance transporter ABCB5 is expressed in human placenta. Int J Gynecol Pathol (2014) 0.78
Role of CD44high/CD133high HCT-116 cells in the tumorigenesis of colon cancer. Oncotarget (2016) 0.77
Tyrosine phosphorylation of HSC70 and its interaction with RFC mediates methotrexate resistance in murine L1210 leukemia cells. Cancer Lett (2014) 0.76
Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics J (2016) 0.76
Upregulation of cellular glutathione levels in human ABCB5- and murine Abcb5-transfected cells. BMC Pharmacol Toxicol (2015) 0.75
Expression of Multidrug Resistance Transporter ABCB5 in a Murine Model of Human Conjunctival Melanoma. Ocul Oncol Pathol (2015) 0.75
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. Cell Death Discov (2017) 0.75
Elevated expression of ABCB5 in ocular surface squamous neoplasia. Sci Rep (2016) 0.75
Effects of Malignant Melanoma Initiating Cells on T-Cell Activation. Methods Mol Biol (2016) 0.75
Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells. Front Pharmacol (2015) 0.75
ABCB5-Targeted Chemoresistance Reversal Inhibits Merkel Cell Carcinoma Growth. J Invest Dermatol (2016) 0.75
KNOCKDOWN OF HOST ANTIOXIDANT DEFENSE GENES ENHANCES THE EFFECT OF GLUCANTIME ON INTRACELLULAR Leishmania braziliensis IN HUMAN MACROPHAGES. Antimicrob Agents Chemother (2017) 0.75
The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study. J Cancer Res Clin Oncol (2014) 0.75
The Implications and Future Perspectives of Nanomedicine for Cancer Stem Cell Targeted Therapies. Front Mol Biosci (2017) 0.75
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Identification of cells initiating human melanomas. Nature (2008) 8.28
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (2003) 4.20
Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med (2003) 4.12
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
The therapeutic promise of the cancer stem cell concept. J Clin Invest (2010) 3.26
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med (2003) 3.00
Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity (2003) 2.80
CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol (2003) 2.79
Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A (2008) 2.73
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol (2009) 2.56
A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol (2006) 2.46
Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest (2011) 2.40
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med (2008) 2.26
Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes (2008) 2.25
Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol (2009) 2.15
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med (2007) 1.93
The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity (2004) 1.85
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol (2002) 1.81
Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol (2003) 1.81
Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A (2007) 1.81
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest (2003) 1.76
Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest (2003) 1.66
Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res (2008) 1.65
Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes (2008) 1.63
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.62
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol (2005) 1.58
T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev (2003) 1.57
The in vitro spheroid melanoma cell culture assay: cues on tumor initiation? J Invest Dermatol (2010) 1.53
Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev (2009) 1.52
PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51
Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol (2006) 1.51
The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest (2008) 1.50
Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol (2006) 1.45
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol (2006) 1.44
Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells. Clin Immunol (2008) 1.43
Regulation of myogenic progenitor proliferation in human fetal skeletal muscle by BMP4 and its antagonist Gremlin. J Cell Biol (2006) 1.42
Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol (2006) 1.42
Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen. Clin Immunol (2010) 1.42
Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol (2008) 1.41
The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol (2002) 1.38
Maternal acceptance of the fetus: true human tolerance. J Immunol (2007) 1.37
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol (2005) 1.32
Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol (2003) 1.31
Increased CD4+ CD25+ T regulatory cell activity in trauma patients depresses protective Th1 immunity. Ann Surg (2006) 1.31
Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol (2003) 1.30
Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood (2005) 1.28
The pro-apoptotic protein Bim is a microRNA target in kidney progenitors. J Am Soc Nephrol (2011) 1.27
The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest (2003) 1.26
Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes (2010) 1.24
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. Cancer Res (2011) 1.23
New reagents on the horizon for immune tolerance. Annu Rev Med (2007) 1.22
Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol (2004) 1.22
Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol (2004) 1.19
Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol (2006) 1.19
Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol (2004) 1.19
A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes (2010) 1.18
Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection. J Immunol (2004) 1.17
Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation (2008) 1.16
Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int (2003) 1.15
Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest (2002) 1.15
Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun (2010) 1.13
New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg (2002) 1.12
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest (2002) 1.12
Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol (2002) 1.12
A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol (2007) 1.12
Combination treatment with donor-specific transfusions and cyclosporine a induces long-term survival of cardiac allografts in miniature Swine. Transplantation (2005) 1.12
CD4+ T cells regulate surgical and postinfectious adhesion formation. J Exp Med (2002) 1.11
Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol (2007) 1.11
The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol (2011) 1.10
Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol (2004) 1.09
Immunosuppressive drugs and Tregs: a critical evaluation! Clin J Am Soc Nephrol (2009) 1.08
T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation (2005) 1.07
T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation (2002) 1.06
Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A (2009) 1.06
Immunomodulatory functions of mesenchymal stem cells. Lancet (2004) 1.06
CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol (2005) 1.06
Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol (2004) 1.05
Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts. J Biophotonics (2012) 1.05
Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol (2010) 1.04
Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol (2007) 1.04
The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes (2002) 1.04
Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes (2007) 1.04
Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol (2008) 1.03
The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol (2003) 1.02